Dabigatran etexilate is a new oral direct thrombin inhibitor that may provide an alternative to warfarin; it has the advantage of not requiring regular monitoring.Compared with warfarin, the ICERs for use of low dose dabigatran in the over-80s were £24 340 and £27 940 per QALY gained for the two...